tetano
Editor, Senior Moderator
Clin Vaccine Immunol. 2011 Jul 27. [Epub ahead of print]
LONG-TERM IMMUNOGENICITY AFTER ONE AND TWO DOSES OF MONOVALENT MF59-ADJUVANTED A/H1N1 INFLUENZA VACCINE CO-ADMINISTERED WITH THE SEASONAL 2009-2010 NON-ADJUVANTED INFLUENZA VACCINE IN HIV-INFECTED CHILDREN, ADOLESCENTS AND YOUNG ADULTS: RANDOMIZED CONTROLLED TRIAL.
Vigan? A, Giacomet V, Pariani E, Giani E, Manfredini V, Bedogni G, Erba P, Amendola A, Zanetti A, Zuccotti G.
Source
Pediatric Clinic, "L. Sacco" Hospital, University of Milan, Milan, Italy.
Abstract
Background: Few data are available on the safety and long-term immunogenicity of A/H1N1 pandemic influenza vaccines in HIV-infected pediatric patients. We performed a randomized controlled trial to evaluate the safety and long-term immunogenicity of 1 vs. 2 doses of the 2009 monovalent pandemic influenza A/H1N1 MF59-adjuvanted vaccine (PV) co-administered with the seasonal 2009-2010 trivalent non-adjuvanted influenza vaccine (SV) in HIV-infected children, adolescents and young adults. Methods: 66 HIV-infected patients aged 9 to 26 years were randomized to receive one (group 1) or two (group 2) doses of PV co-administered with 1 dose of SV. The main outcome was the seroconversion rate for PV at 1 month. Secondary outcomes were the geometric mean titer ratios and the seroprotection rates at 1 month for all vaccines, seroconversion rates at 1 month for SV and longitudinal changes of antibody titers (ABTs) at 1, 2, 6 and 12 months for all vaccines. Results: Groups 1 and 2 had similar CD4 counts and HIV-RNA levels during the study. Seroconversion rates for PV were 100% at 1 month in both groups. ABTs for PV were high during the first 6 months and declined below seroprotection levels thereafter. Longitudinal changes in ABTs were similar in Groups 1 and 2 for both PV and SV. Side-effects of vaccination were mild and mostly local. Conclusions: In HIV-infected children, adolescents, and young adults the immune response triggered by a single dose of PV was similar to that obtained with a double dose and associated with long-term antibody response.
PMID:
21795458
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21795458
LONG-TERM IMMUNOGENICITY AFTER ONE AND TWO DOSES OF MONOVALENT MF59-ADJUVANTED A/H1N1 INFLUENZA VACCINE CO-ADMINISTERED WITH THE SEASONAL 2009-2010 NON-ADJUVANTED INFLUENZA VACCINE IN HIV-INFECTED CHILDREN, ADOLESCENTS AND YOUNG ADULTS: RANDOMIZED CONTROLLED TRIAL.
Vigan? A, Giacomet V, Pariani E, Giani E, Manfredini V, Bedogni G, Erba P, Amendola A, Zanetti A, Zuccotti G.
Source
Pediatric Clinic, "L. Sacco" Hospital, University of Milan, Milan, Italy.
Abstract
Background: Few data are available on the safety and long-term immunogenicity of A/H1N1 pandemic influenza vaccines in HIV-infected pediatric patients. We performed a randomized controlled trial to evaluate the safety and long-term immunogenicity of 1 vs. 2 doses of the 2009 monovalent pandemic influenza A/H1N1 MF59-adjuvanted vaccine (PV) co-administered with the seasonal 2009-2010 trivalent non-adjuvanted influenza vaccine (SV) in HIV-infected children, adolescents and young adults. Methods: 66 HIV-infected patients aged 9 to 26 years were randomized to receive one (group 1) or two (group 2) doses of PV co-administered with 1 dose of SV. The main outcome was the seroconversion rate for PV at 1 month. Secondary outcomes were the geometric mean titer ratios and the seroprotection rates at 1 month for all vaccines, seroconversion rates at 1 month for SV and longitudinal changes of antibody titers (ABTs) at 1, 2, 6 and 12 months for all vaccines. Results: Groups 1 and 2 had similar CD4 counts and HIV-RNA levels during the study. Seroconversion rates for PV were 100% at 1 month in both groups. ABTs for PV were high during the first 6 months and declined below seroprotection levels thereafter. Longitudinal changes in ABTs were similar in Groups 1 and 2 for both PV and SV. Side-effects of vaccination were mild and mostly local. Conclusions: In HIV-infected children, adolescents, and young adults the immune response triggered by a single dose of PV was similar to that obtained with a double dose and associated with long-term antibody response.
PMID:
21795458
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21795458